Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program

PURPOSE: The primary objective of this study was to evaluate 1- and 2-year survival rates and durable remissions in pretreated patients with advanced (unresectable or metastatic) malignant melanoma treated with ipilimumab in a South African expanded-access program (SA-EAP). PATIENTS AND METHODS: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rapoport, Bernardo L., Vorobiof, Daniel A., Dreosti, Lydia M., Nosworthy, Adam, McAdam, Georgina, Jordaan, Johan P., Miller-Jansön, Helen, de Necker, Margreet, de Beer, Janetta C., Duvenhage, Hennie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2016
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646890/
https://www.ncbi.nlm.nih.gov/pubmed/29094091
http://dx.doi.org/10.1200/JGO.2016.006544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646890/
https://www.ncbi.nlm.nih.gov/pubmed/29094091
http://dx.doi.org/10.1200/JGO.2016.006544

Ejemplares similares